Literature DB >> 16273214

Evaluation of p16 and Id1 status and endogenous reference genes in human chondrosarcoma by real-time PCR.

Julia Asp1, Camilla Brantsing, Karina Lövstedt, Maria Serena Benassi, Sven Inerot, Gabriella Gamberi, Piero Picci, Anders Lindahl.   

Abstract

Both the tumour suppressor, p16, and the helix-loop-helix transcription factor, Id1, have been assigned roles in tumour growth in general and appear to be involved in chondrosarcoma. Id1 has further been found to repress the expression of p16. Therefore, the mRNA expression of these two genes was studied by real-time PCR in a search for prognostic markers in human chondrosarcoma. To get reliable quantitative data, however, the choice of endogenous reference gene for use in the assay is important. Therefore, eleven different endogenous reference genes were evaluated in chondrosarcoma cells and articular chondrocytes. 18S rRNA appeared to be the best choice to use as endogenous reference gene, since it was suitable for both kinds of cells. Several of the other reference genes tested showed variation between individuals or between normal chondrocytes and chondrosarcoma cells. This demonstrates the importance of using a correct endogenous reference gene to get reliable results from quantitative measurements. Both p16 and Id1 showed varied gene expression patterns among the samples and none of these genes could be significantly correlated to prognosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16273214

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

Review 1.  Genetic alterations in chondrosarcomas - keys to targeted therapies?

Authors:  Andre M Samuel; Jose Costa; Dieter M Lindskog
Journal:  Cell Oncol (Dordr)       Date:  2014-01-24       Impact factor: 6.730

2.  CXCR4-targeted therapy inhibits VEGF expression and chondrosarcoma angiogenesis and metastasis.

Authors:  Xiaojuan Sun; Cherie Charbonneau; Lei Wei; Wentian Yang; Qian Chen; Richard M Terek
Journal:  Mol Cancer Ther       Date:  2013-05-17       Impact factor: 6.261

3.  HDAC4 represses vascular endothelial growth factor expression in chondrosarcoma by modulating RUNX2 activity.

Authors:  Xiaojuan Sun; Lei Wei; Qian Chen; Richard M Terek
Journal:  J Biol Chem       Date:  2009-06-09       Impact factor: 5.157

4.  Selection of reliable reference genes for qPCR studies on chondroprotective action.

Authors:  Stefan Toegel; Wenwen Huang; Claudia Piana; Frank M Unger; Michael Wirth; Mary B Goldring; Franz Gabor; Helmut Viernstein
Journal:  BMC Mol Biol       Date:  2007-02-26       Impact factor: 2.946

5.  ID1 contributes to cell growth invasion and migration in salivary adenoid cystic carcinoma.

Authors:  Xiao-Meng Hu; Ting Lin; Xiao-Yu Huang; Rui-Huan Gan; Yong Zhao; Yan Feng; Lin-Can Ding; Bo-Hua Su; Da-Li Zheng; You-Guang Lu
Journal:  Mol Med Rep       Date:  2017-10-09       Impact factor: 2.952

6.  CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression.

Authors:  Xiaojuan Sun; Lei Wei; Qian Chen; Richard M Terek
Journal:  Mol Cancer       Date:  2010-01-26       Impact factor: 27.401

7.  Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone.

Authors:  Jolieke G van Oosterwijk; Danielle de Jong; Maayke A J H van Ruler; Pancras C W Hogendoorn; P D Sander Dijkstra; Carla S P van Rijswijk; Isidro Machado; Antonio Llombart-Bosch; Karoly Szuhai; Judith V M G Bovée
Journal:  BMC Cancer       Date:  2012-08-28       Impact factor: 4.430

8.  Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro.

Authors:  Yvonne M Schrage; Suzanne Lam; Aart G Jochemsen; Anne-Marie Cleton-Jansen; Antonie H M Taminiau; Pancras C W Hogendoorn; Judith V M G Bovée
Journal:  J Cell Mol Med       Date:  2008-06-27       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.